FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology. Eukaryotic cells are transduced by retrovirus in the presence of the primer protein bis-meth-histone I 1.3. The method enables higher effectiveness of retroviral transduction and avoided disadvantages of the analogues.
EFFECT: invention may be used in medicine, veterinary science, biology for producing drug preparations for in vitro/ex vivo gene therapy and gene modification of cells.
6 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USING HISTONE PROTEIN AS ADENOVIRAL TRANSDUCTION INHIBITOR | 2014 |
|
RU2555553C1 |
| COMPOSITIONS INCREASING THE NUMBER OF COPIES OF THE VECTOR (VCN), AND METHODS OF USING | 2017 |
|
RU2744603C2 |
| VIRAL PARTICLES CONTAINING ALPHAVIRUS VECTOR AND METHOD FOR PREPARING SAID VIRAL PARTICLE | 2004 |
|
RU2398875C2 |
| METHOD FOR TEMPORARY TRANSFECTION FOR PRODUCING RETROVIRUS | 2016 |
|
RU2749717C2 |
| LENTIVIRAL VECTORS PSEUDOTYPED BY MUTANT BaEV GLYCOPROTEINS | 2012 |
|
RU2618864C2 |
| METHOD OF OBTAINING RECOMBINANT VESICULAR STOMATITIS VIRUS | 2022 |
|
RU2807751C1 |
| DOUBLE VECTOR FOR SUPPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS | 2010 |
|
RU2562868C2 |
| STABLE PRODUCTION OF LENTIVIRUS VECTORS | 2011 |
|
RU2577979C2 |
| STABLE CELL LINES FOR RETROVIRUSES PRODUCTION | 2016 |
|
RU2752498C2 |
| VIRAL VECTORS WITH CONDITION-DEPENDENT REPLICATION AND THEIR USING | 2001 |
|
RU2301260C2 |
